The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma (Q84230583)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 May 2011

Language	Label	Description	Also known as
English	The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma	scientific article published on 28 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Daigo Kawano

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Tokujiro Yano

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Fumihiro Shoji

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kensaku Ito

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Yosuke Morodomi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Akira Haro

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Naoko Miura

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Tomoyoshi Takenaka

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ichiro Yoshino

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Yoshihiko Maehara

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

28 May 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

41

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

818-823

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

The EGF receptor family as targets for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status

1 reference

https://pubmed.ncbi.nlm.nih.gov/21626329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00595-011-4514-2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21626329%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84230583&oldid=1409569196"